A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spontaneous Urticaria
Key facts
- Who runs it
- Sanofi
- Where
- Wilmington, United StatesSee the site
- Trial code
- NCT07316114
- U1111-1331-3693
- Status
- Terminated
- People taking part
- 1 person enrolled
- Started
- 18 Mar 2026
- Ended
- 2 Jun 2026
- Type of study
- Observational
- Treatments tested
- Dupilumab
- Record updated
- 31 July 2026
- Why it stopped
- Sponsor decision; the decision is not related to any safety concern.
Who can take part
- Age
- 12 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Patients aged 12 years or older at the time of informed consent/assent
- Physician decision to treat the patient with dupilumab for chronic spontaneous urticaria (CSU) made prior to and independently of the patient's participation in the study
- Patient is able to understand and complete study-related questionnaires
- Patients and/or parent/legally authorized representative provide voluntary informed consent and/or assent to participate in the study before inclusion in the study
Who cannot take part
- Prior use of dupilumab within 6 months of the baseline assessment; The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial
- Any condition that the treating physician or virtual Investigator believes may interfere with the patient's ability to participate in the study, such as short life expectancy, substance abuse, severe cognitive impairment, or other comorbidities that can predictably prevent the patient from completing the schedule of assessments
- Patients who have a contraindication to dupilumab according to the approved prescribing information label
- Patients currently participating in any interventional clinical trial
Where in United States
- Virtual Research Coordination CenterWilmington, United States
About the trial
What the trial wants to find out
This is a decentralized study designed to describe the real-world effectiveness, safety, and patterns of use of dupilumab in patients with chronic spontaneous urticaria (CSU). This study will be conducted in the United States and will collect data available from participants' medical files, other items routinely collected during disease management in clinical practice, and patient-reported outcomes related to disease, work productivity, quality of life, and CSU-related hospitalizations.
Read full original descriptionShow less
Participation in this study is the patient's own choice and is entirely voluntary. The treating physician prescribes dupilumab treatment as part of routine care, independently of the study. Once the decision to prescribe dupilumab is made by the treating physician, patients can self-screen and will be contacted by the Virtual Research Coordination Center to determine potential study eligibility. Patients will be enrolled if they provide an informed consent and meet all inclusion criteria and none of the exclusion criteria.
The duration of the study for each participant is 24 months. All patients will be followed for 24 months or until death, loss to follow-up, or withdrawal, whichever occurs first.
Treatments tested
- Dupilumab
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Prospective Observational Study of Patients Receiving Dupilumab for Chronic Spontaneous Urticaria
- Record updated
- 31 July 2026